{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"muscle-invasive bladder cancer","name":"PANDORE","nct_id":"NCT03212651","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pandore-nct03212651. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PANDORE","arms":[{"description":"Cisplatinum-ineligible patients with muscle-invasive bladder cancer","label":"Patients with MIBC (Muscle Invasive Bladder Cancer)","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2019-12-13","type":"ACTUAL"},"conditions":["Bladder Cancer"],"enrollment":{"count":41,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2023-01-20","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","official_title":"A Phase II Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2019-07-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathologic complete response rate","timeFrame":"Up to 1 month"}],"references":[],"start_date":{"date":"2017-10-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab","url":"https://clinicaltrials.gov/study/NCT03212651"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pandore-nct03212651"}